Total expenses jumped 36.85% to Rs 1476.2 crore with cost of materials consumed climbing 32.46% to Rs 901.16 crore during the period under review.

For the 9-month period ended 31 December 2021, the company earned a PAT of Rs 2066 crore on a total income of Rs 6503 crore, as against a PAT of Rs 1482 crore on a total income of Rs 5224 crore during the corresponding previous period.

Divi's Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates, and nutraceutical ingredients.